2020 US Medicinal Products
Financial Strength Rankings using Artificial Intelligence
Top rated | 13 of 52 |
Best rating | 220 % |
Worst rating | -490 % |
New companies | 7 |
Negative Economic Capital Ratio | 17 of 52 |
Financial Strength Rankings using Artificial Intelligence
Top rated | 13 of 52 |
Best rating | 220 % |
Worst rating | -490 % |
New companies | 7 |
Negative Economic Capital Ratio | 17 of 52 |
Phoenix Life Sciences International Limited. climbed 29 positions from 43 to 14 due to its excellent Goodwill.MARIMED INC. lost 36 positions from 9 to 45 due to its bad Assets, Current.Cronos Group Inc. entered the 2020 ranking at rank 1, making it the best newcomer.
Revenues | 37.3 B |
Assets | 60.1 B |
Expenses | 36.0 B |
Stockholders Equity | 24.7 B |
Unprofitable Companies | 33 of 52 |
Photo source: https://openai.com/dall-e-3/ RealRate is excited to announce that the new 2024 [...]
We are extremely excited to announce that an interview with Holger Bartel has [...]
On February 14th, 2024, something momentous happened. Nvidia, the chip and graphics card [...]
Source: https://openai.com/dall-e-3/ The results for RealRate’s 2023 ranking for U.S. Pharma are [...]
Source: https://openai.com/dall-e-3/ The results for RealRate’s 2023 ranking for U.S. Savings are [...]
Source: https://openai.com/dall-e-3/ The results for RealRate’s 2023 ranking for U.S. Chemicals are [...]
Source: https://openai.com/dall-e-3/ The machines have emerged and the results for RealRate’s 2023 [...]
Source: https://openai.com/dall-e-2/ The results for RealRate’s 2023 ranking for U.S. Medicinal Products [...]
This year's rating information is fee-based. Please request rates at
james.woods@realrate.ai